Financhill
Buy
60

EQ Quote, Financials, Valuation and Earnings

Last price:
$1.34
Seasonality move :
25.95%
Day range:
$1.25 - $1.53
52-week range:
$0.27 - $2.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.71x
P/B ratio:
2.76x
Volume:
2.9M
Avg. volume:
605K
1-year change:
130.26%
Market cap:
$85.3M
Revenue:
$41.1M
EPS (TTM):
-$0.63

Analysts' Opinion

  • Consensus Rating
    Equillium, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $2.50, Equillium, Inc. has an estimated upside of 78.57% from its current price of $1.40.
  • Price Target Downside
    According to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $1.40.

Fair Value

  • According to the consensus of 3 analysts, Equillium, Inc. has 78.57% upside to fair value with a price target of $2.50 per share.

EQ vs. S&P 500

  • Over the past 5 trading days, Equillium, Inc. has overperformed the S&P 500 by 12.13% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Equillium, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Equillium, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Equillium, Inc. reported revenues of --.

Earnings Growth

  • Equillium, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Equillium, Inc. reported earnings per share of -$0.06.
Enterprise value:
52.9M
EV / Invested capital:
1.67x
Price / LTM sales:
13.71x
EV / EBIT:
--
EV / Revenue:
12.04x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-2.31x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$4.3M
Return On Assets:
-98.6%
Net Income Margin (TTM):
-555.94%
Return On Equity:
-137.47%
Return On Invested Capital:
-134.17%
Operating Margin:
-106.97%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $42.6M $45.9M $4.4M $12.2M --
Gross Profit $42.5M $45.8M $4.3M $12.1M -$28K
Operating Income -$9.3M -$6.8M -$24.4M -$679K -$4.6M
EBITDA -$9.2M -$6.6M -$24.2M -$644K -$4.5M
Diluted EPS -$0.24 -$0.13 -$0.63 -$0.00 -$0.06
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $92.2M $46.8M $53.9M $33.6M $33.6M
Total Assets $92.5M $48.6M $55.2M $34.5M $34.5M
Current Liabilities $7.8M $14.9M $28.2M $11.1M $3.1M
Total Liabilities $16.7M $20.5M $31.1M $11.3M $3.6M
Total Equity $75.8M $28.2M $24.1M $23.2M $30.9M
Total Debt $10.1M $11.3M $498K $223K $473K
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations $11.6M -$21.4M -$22.9M -$7.7M -$8.4M
Cash From Investing $7.8M $2.3M $10.5M $12M --
Cash From Financing -$10.7M $170K $30.2M -- $30.1M
Free Cash Flow $11.6M -$21.5M -$22.9M -$7.7M -$8.4M
EQ
Sector
Market Cap
$85.3M
$28.4M
Price % of 52-Week High
59.57%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
-34.86%
-1.49%
1-Year Price Total Return
130.26%
-16.67%
Beta (5-Year)
1.922
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $1.22
200-day SMA
Buy
Level $0.86
Bollinger Bands (100)
Buy
Level 0.93 - 1.63
Chaikin Money Flow
Sell
Level -1.1M
20-day SMA
Buy
Level $1.04
Relative Strength Index (RSI14)
Buy
Level 64.46
ADX Line
Buy
Level 23.1
Williams %R
Sell
Level -18.1058
50-day SMA
Buy
Level $1.15
MACD (12, 26)
Buy
Level 0.06
25-day Aroon Oscillator
Buy
Level 52
On Balance Volume
Neutral
Level 1.7M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-6.7466)
Sell
CA Score (Annual)
Level (-0.8084)
Sell
Beneish M-Score (Annual)
Level (-0.1158)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (2.6034)
Buy
Piotroski F Score (Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March 2017 and is headquartered in La Jolla, CA.

Stock Forecast FAQ

In the current month, EQ has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The EQ average analyst price target in the past 3 months is $2.50.

  • Where Will Equillium, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Equillium, Inc. share price will rise to $2.50 per share over the next 12 months.

  • What Do Analysts Say About Equillium, Inc.?

    Analysts are divided on their view about Equillium, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Equillium, Inc. is a Sell and believe this share price will drop from its current level to $1.00.

  • What Is Equillium, Inc.'s Price Target?

    The price target for Equillium, Inc. over the next 1-year time period is forecast to be $2.50 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.

  • Is EQ A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Equillium, Inc. is a Hold. 2 of 3 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of EQ?

    You can purchase shares of Equillium, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Equillium, Inc. shares.

  • What Is The Equillium, Inc. Share Price Today?

    Equillium, Inc. was last trading at $1.34 per share. This represents the most recent stock quote for Equillium, Inc.. Yesterday, Equillium, Inc. closed at $1.40 per share.

  • How To Buy Equillium, Inc. Stock Online?

    In order to purchase Equillium, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Is Bloom Energy The Best Stock to Buy Now?
Is Bloom Energy The Best Stock to Buy Now?

Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…

Stock Ideas

Buy
55
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 63x

Buy
53
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 36x

Buy
59
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
60
AAOI alert for Dec 23

Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.

Buy
52
ABVX alert for Dec 23

Abivax SA [ABVX] is down 0.27% over the past day.

Buy
60
ZBIO alert for Dec 23

Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock